1921
The Global Pandemic of Falsified Medicines: Laboratory and Field Innovations and Policy Implications
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Many antimalarials sold in sub-Saharan Africa are poor-quality (falsified, substandard, or degraded), and the burden of disease caused by this problem is inadequately quantified. In this article, we estimate the number of under-five deaths caused by ineffective treatment of malaria associated with consumption of poor-quality antimalarials in 39 sub-Saharan countries. Using Latin hypercube sampling our estimates were calculated as the product of the number of private sector antimalarials consumed by malaria-positive children in 2013; the proportion of private sector antimalarials consumed that were of poor-quality; and the case fatality rate (CFR) of under-five malaria-positive children who did not receive appropriate treatment. An estimated 122,350 (interquartile range [IQR]: 91,577–154,736) under-five malaria deaths were associated with consumption of poor-quality antimalarials, representing 3.75% (IQR: 2.81–4.75%) of all under-five deaths in our sample of 39 countries. There is considerable uncertainty surrounding our results because of gaps in data on case fatality rates and prevalence of poor-quality antimalarials. Our analysis highlights the need for further investigation into the distribution of poor-quality antimalarials and the need for stronger surveillance and regulatory efforts to prevent the sale of poor-quality antimalarials.

[open-access] This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.14-0725
2015-06-03
2017-09-21
Loading full text...

Full text loading...

/deliver/fulltext/14761645/92/6_Suppl/119.html?itemId=/content/journals/10.4269/ajtmh.14-0725&mimeType=html&fmt=ahah

References

  1. World Health Organization, 2013. World Malaria Report 2013. Geneva, Switzerland: WHO. Available at: http://apps.who.int/iris/bitstream/10665/97008/1/9789241564694_eng.pdf. Accessed March 13, 2014.
  2. Murray C, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD, , 2012. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379: 413431.[Crossref]
  3. Nayyar GM, Breman JG, Newton PN, Herrington J, , 2012. Poor-quality antimalarial drugs in southeast Asia and sub-Saharan Africa. Lancet Infect Dis 12: 488496.[Crossref]
  4. Eastman RT, Fidock DA, , 2009. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol 7: 864874.
  5. White NJ, , 2008. Qinghaosu (artemisinin): the price of success. Science 320: 330334.[Crossref]
  6. Flegg JA, Metcalf CJE, Gharbi M, Venkatesan M, Shewchuk T, Hopkins Sibley C, Guerin PJ, , 2013. Trends in antimalarial drug use in Africa. Am J Trop Med Hyg 89: 857865.[Crossref]
  7. O'Connell KA, Gatakaa H, Poyer S, Njogu J, Evance I, Munroe E, Solomon T, Goodman C, Hanson K, Zinsou C, , 2011. Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries. Malar J 10: 326.[Crossref]
  8. Newton P, Green M, Mildenhall D, Plancon A, Nettey H, Nyadong L, Hostetler D, Swamidoss I, Harris G, Powell K, Timmermans A, Amin A, Opuni S, Barbereau S, Faurant C, Soong R, Faure K, Thevanayagam J, Fernandes P, Kaur H, Angus B, Stepniewska K, Guerin P, Fernandez F, , 2011. Poor quality vital anti-malarials in Africa—an urgent neglected public health priority. Malar J 10: 352.[Crossref]
  9. Institute of Medicine, 2013. Countering the Problem of Falsified and Substandard Drugs. Washington, DC: The National Academies Press.
  10. Tabernero P, Fernández FM, Green M, Guerin PJ, Newton PN, , 2014. Mind the gaps-the epidemiology of poor-quality anti-malarials in the malarious world-analysis of the Worldwide Antimalarial Resistance Network database. Malar J 13: 139.[Crossref]
  11. Newton PN, Green MD, Fernández FM, , 2010. Impact of poor-quality medicines in the “developing” world. Trends Pharmacol Sci 31: 99101.[Crossref]
  12. World Health Organization, 2013. What Encourages Counterfeiting of Medicines? Available at: https://www.wiltonpark.org.uk/wp-content/uploads/WP1185-WHO-What-encourages-counterfeiting-of-medicines.pdf. Accessed October 3, 2013.
  13. Cohen JM, Woolsey AM, Sabot OJ, Gething PW, Tatem AJ, Moonen B, , 2012. Optimizing investments in malaria treatment and diagnosis. Science 338: 612614.[Crossref]
  14. World Health Organization, 2014. Falsified Antimalarial Medicines in West and Central Africa. Geneva, Switzerland: WHO. Available at: http://www.who.int/medicines/publications/drugalerts/Alert_131_antimalarials_essential_drugs_programme_pre_final.pdf. Accessed September 7, 2014.
  15. World Health Organization, 2013. Falsified Batches of Coartem Recently Circulating in Cameroon. Geneva, Switzerland: WHO. Available at: http://www.who.int/medicines/publications/drugalerts/Alert_130_Information_Coartem_VF.pdf.
  16. Keoluangkhot V, Green MD, Nyadong L, Fernández FM, Mayxay M, Newton PN, , 2008. Impaired clinical response in a patient with uncomplicated falciparum malaria who received poor-quality and underdosed intramuscular artemether. Am J Trop Med Hyg 78: 552555.
  17. White NJ, Pongtavornpinyo W, Maude RJ, Saralamba S, Aguas R, Stepniewska K, Lee SJ, Dondorp AM, White LJ, Day NP, , 2009. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar J 8: 253.[Crossref]
  18. Newton PN, Fernández FM, Green MD, Primo-Carpenter J, White NJ, Sosa AJ, Byarugaba DK, Amábile-Cuevas CF, Hsueh P-R, Kariuki S, Okeke IN, , 2010. Counterfeit and substandard anti-infectives in developing countries. , eds. Antimicrobial Resistance in Developing Countries. New York, NY: Springer, 413443. Available at: http://www.springerlink.com/index/10.1007/978-0-387-89370-9_24. Accessed December 1, 2013.[Crossref]
  19. Blower SM, Dowlatabadi H, , 1994. Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model, as an example. Int Stat Rev 62: 229243.[Crossref]
  20. U.S. Pharmacopeia, 2009. Survey of the Quality of Selected Antimalarial Medicines Circulating in Madagascar, Senegal, and Uganda. Available at: http://apps.who.int/medicinedocs/documents/s17069e/s17069e.pdf. Accessed October 3, 2013.
  21. World Health Organization, 2011. Survey of the Quality of Selected Antimalarial Medicines Circulating in Six Countries of Sub-Saharan Africa. Available at: http://www.who.int/medicines/publications/WHO_QAMSA_report.pdf. Accessed October 3, 2013.
  22. Cairns M, Roca-Feltrer A, Garske T, Wilson AL, Diallo D, Milligan PJ, Ghani AC, Greenwood BM, , 2012. Estimating the potential public health impact of seasonal malaria chemoprevention in African children. Nat Commun 3: 881.[Crossref]
  23. Lubell Y, Staedke SG, Greenwood BM, Kamya MR, Molyneux M, Newton PN, Reyburn H, Snow RW, D'Alessandro U, English M, Day N, Kremsner P, Dondorp A, Mbacham W, Dorsey G, Owusu-Agyei S, Maitland K, Krishna S, Newton C, Pasvol G, Taylor T, von Seidlein L, White NJ, Binka F, Mills A, Whitty CJM, , 2011. Likely health outcomes for untreated acute febrile illness in the tropics in decision and economic models; a Delphi survey. PLoS ONE 6: e17439.[Crossref]
  24. World Health Organization, 2008. World Malaria Report. Geneva, Switzerland: World Health Organization Global Malaria Programme.
  25. Taberno P, Netwon PN, , 2012. The WWARN antimalarial quality surveyor. Pathog Glob Health 106: 7778.[Crossref]
  26. Shewchuk T, O'Connell KA, Goodman C, Hanson K, Chapman S, Chavasse D, , 2011. The ACTwatch project: methods to describe anti-malarial markets in seven countries. Malar J 10: 325.[Crossref]
  27. Smith D, Klein E, McKenzie FE, Laxminarayan R, , 2010. Prospective strategies to delay the evolution of anti-malarial drug resistance: weighing the uncertainty. Malar J 9: 217.[Crossref]
  28. Siva N, , 2010. Tackling the booming trade in counterfeit drugs. Lancet 376: 17251726.[Crossref]
  29. Newton PN, Amin AA, Bird C, Passmore P, Dukes G, Tomson G, Simons B, Bate R, Guerin PJ, White NJ, , 2011. The primacy of public health considerations in defining poor quality medicines. PLoS Med 8: e1001139.[Crossref]
  30. Newton PN, Lee SJ, Goodman C, Fernandez FM, Yeung S, Phanouvong S, Kaur H, Amin AA, Whitty CJM, Kokwaro GO, Lukulay P, White LJ, Day NPJ, Green MD, White NJ, , 2009. Guidelines for field surveys of the quality of medicines: a proposal. PLoS Med 6: e1000052.[Crossref]
  31. World Health Organization, 2011. Medicines: Spurious/Falsely-Labelled/ Falsified/Counterfeit (SFFC) Medicines. Fact Sheet 275. Geneva, Switzerland: WHO. Available at: http://www.who.int/mediacentre/factsheets/fs275/en/. Accessed January 27, 2014.
  32. World Health Organization. Counterfeit FAQs: How Do Substandard Medicines Arise? Available at: http://who.int/medicines/services/counterfeit/faqs/05/en/index.html. Accessed January 27, 2014.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.14-0725
Loading
/content/journals/10.4269/ajtmh.14-0725
Loading

Data & Media loading...

Supplementary Data

Supplementary PDF

  • Received : 18 Nov 2014
  • Accepted : 03 Apr 2015

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error